Celgene Reports Second Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Celgene Reports Second Quarter 2015 Operating and Financial Results
July 24, 2015 10:40 AM EDT
Nomura Securities analyst M. Ian Somaiya reiterated his Buy rating and boosted his price target on Celgene (NASDAQ: CELG) to $167.00 (from $165.00) following 2Q earnings, which saw largely in-line revenue, but an EPS beat on continued operating leverage.
Somaiya commented, "We believe... More
July 23, 2015 11:19 AM EDT
Cowen analyst Eric Schmidt bumped his price target on Outperform-rated Celgene (NASDAQ: CELG) to $150.00 (from $146.00) following solid Q2 results.
Schmidt commented, "Celgene reported Q2 sales of $2.254B (+22% Y/Y) and non-GAAP EPS $1.17 (+30% Y/Y, excluding 1x gain of $0.06), in-line with its... More
July 23, 2015 7:41 AM EDT
Celgene (NASDAQ: CELG ) reported Q2 EPS of $1.23, $0.04 better than the analyst estimate of $1.19. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.26 billion.
Celgene sees FY2015 EPS of $4.75-$4.85, versus prior guidance of $4.60-$4.75 and the consensus of $4.79. Celgene sees FY2015 revenue of $9-9.5... More
